2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3090 Evaluation of factors associated with anticoagulation adherence in children

Hope P. Wilson, MD, A K M Fazlur Rahman, PhD2, Jeffrey Lebensburger, DO3
1 University of Alabama Heersink School of Medicine, Birmingham, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama Heersink School of Medicine, Birmingham, United States

Background
The cornerstone of pediatric venous thromboembolism (VTE) treatment is anticoagulation to stabilize the thrombus and promote resolution. However, daily anticoagulation use poses challenges to patients and families. Prior studies have reported that anywhere from 3-42% of children and young adults are non-adherent to their anticoagulation regimens due to various barriers. It has been established that high medication adherence is critical to achieve successful outcomes in other pediatric populations such as pediatric leukemia. Data is limited in pediatric VTE patients. The role of anticoagulation adherence on VTE outcomes has not been fully explored in children.

Methods
We conducted a six-month prospective observational study of children <21 years old with a first provoked VTE treated at the pediatric thrombosis clinic at the University of Alabama at Birmingham (UAB) and Children’s of Alabama. The primary aim of this study was to characterize clinical and sociodemographic factors associated with anticoagulation adherence and nonadherence in children <21 years old. We also sought to identify associations between anticoagulation nonadherence and VTE outcomes.This study was approved by the institutional review board at UAB.

Upon enrollment, parents of all participants completed a social determinant of health (SDOH) questionnaire. Barriers to medication adherence were assessed at enrollment and at the end of therapy utilizing questions adapted for anticoagulation from the Parent Medication Barrier Scale and the Adolescent Medication Barrier Scale. These were completed by parents and adolescents > 12 years old, respectively.  Adherence was assessed via self-report utilizing daily medication diaries and with the MARS5 validated tool. Nonadherence was defined a priori as missing >20% of prescribed doses  or any reported nonadherence on the MARS-5 (score <25).

Descriptive statistics are presented as mean (standard deviation, SD) or median (interquartile range, IQR) for continuous variables and frequency (%) for categorical variables. Characteristics were reported overall and by adherence category. Statistical analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC).

Results
There were 21 participants enrolled. Fourteen (67%) were classified as adherent and the remaining seven (33%) were nonadherent. The majority (95.2%) of participants were White and non Hispanic/Latino. The most common provoking factor overall was infection. Rivaroxaban was the most commonly used anticoagulant. No participant had recurrent VTE.

When compared to participants in the adherent group, those who were nonadherent were younger with a median age of 6.11 years (IQR 0.8-17 years) versus a median age of 11.5 years (IQR 3.3-14.3 years), had a higher proportion of cerebral sinus venous thrombosis and upper extremity deep vein thrombosis and were more likely to receive three months of anticoagulant treatment. There were no differences in thrombus resolution between groups.

Regarding SDOH, parents of participants in the nonadherent group were older with a median age of 40 (IQR 29-52 years) as compared to parents of participants in the adherent group 37 (IQR 30-43 years) and were more likely to have a high school diploma or GED.

Conclusion
Our preliminary findings from this prospective cohort study evaluating anticoagulant adherence are consistent with prior pediatric data identifying younger patient age and low parental education level to be associated with nonadherence. Although we did not identify any differences in outcomes in the nonadherent participants, larger prospective studies with longer follow-up are warranted to definitively investigate the association between anticoagulation nonadherence and pediatric VTE outcomes and to determine the threshold by which outcomes may be compromised.

Hope P. Wilson, MD: No relevant conflicts of interest to declare.